BioSpace News Archive

Novo Nordisk’s investment of more than half a billion dollars is meant to expand its production capabilities in China and help it meet the global drug demand.

Two days after winning FDA approval, Orchard Therapeutics on Wednesday provided its U.S. launch plans for metachromatic leukodystrophy gene therapy Lenmeldy, which has a wholesale acquisition cost of $4.25 million for the one-time treatment.

Bristol Myers Squibb secured another late-phase immuno-oncology victory Wednesday, showing that the combination of Opdivo and Yervoy improved overall survival in a patient population served by rival checkpoint inhibitors from AstraZeneca and Roche.

Nicox SA announced that the results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.

ProVerum Limited announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate the safety and effectiveness of the ProVee System, a ‘stent-like’ expander designed to gently ‘open-up’ the obstructed urethra and alleviate the symptoms caused by BPH.

Agendia®, Inc. announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.

Immunic, Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for patent application 16/981,122, entitled, “Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents,” covering the composition-of-matter of a specific polymorph of vidofludimus calcium and a related method of production of the material.

Zomedica Corp., a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Monday, April 1st, 2024, at 4:30 p.m. ET to discuss the Company’s operational and financial highlights for its fourth quarter and full year ended December 31, 2023.

TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced the sale of its distribution rights related to NIVIS Fibrillar Collagen Pack to Atlanta-based MiMedx Group, Inc.

MiMedx Group, Inc. announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity Biosciences that will enable the Company to add xenograft products to its portfolio of Advanced Wound Care and Surgical solutions.